Monopar Therapeutics Inc. (MNPR)
MNPR Stock Price Chart
Explore Monopar Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze MNPR price movements and trends.
MNPR Company Profile
Discover essential business fundamentals and corporate details for Monopar Therapeutics Inc. (MNPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Dec 2019
Employees
14.00
Website
https://www.monopartx.comCEO
Chandler D. Robinson MBA, MSc
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
MNPR Financial Timeline
Browse a chronological timeline of Monopar Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.49.
Earnings released on 12 Aug 2025
EPS came in at -$0.35 surpassing the estimated -$0.47 by +25.53%.
Earnings released on 13 May 2025
EPS came in at -$0.38 surpassing the estimated -$0.65 by +41.54%.
Earnings released on 31 Mar 2025
EPS came in at -$2.23 falling short of the estimated -$0.36 by -519.44%.
Earnings released on 8 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.46 by +19.57%.
Stock split effective on 13 Aug 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Aug 2024
EPS came in at -$0.50 falling short of the estimated -$0.45 by -11.11%.
Earnings released on 9 May 2024
EPS came in at -$0.50 surpassing the estimated -$0.85 by +41.18%.
Earnings released on 28 Mar 2024
EPS came in at -$0.60 surpassing the estimated -$0.85 by +29.41%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.95 by +26.32%.
Earnings released on 10 Aug 2023
EPS came in at -$0.80 surpassing the estimated -$0.95 by +15.79%.
Earnings released on 11 May 2023
EPS came in at -$0.95 surpassing the estimated -$1.00 by +5.00%.
Earnings released on 23 Mar 2023
EPS came in at -$1.10 falling short of the estimated -$1.05 by -4.76%.
Earnings released on 10 Nov 2022
EPS came in at -$0.95 surpassing the estimated -$1.15 by +17.39%.
Earnings released on 11 Aug 2022
EPS came in at -$1.10 falling short of the estimated -$1.05 by -4.76%.
Earnings released on 12 May 2022
EPS came in at -$0.95 surpassing the estimated -$1.20 by +20.83%.
Earnings released on 24 Mar 2022
EPS came in at -$1.05 falling short of the estimated -$0.90 by -16.67%.
Earnings released on 12 Nov 2021
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 12 Aug 2021
EPS came in at -$0.85 surpassing the estimated -$1.05 by +19.05%.
Earnings released on 13 May 2021
EPS came in at -$0.80 surpassing the estimated -$1.10 by +27.27%.
Earnings released on 25 Mar 2021
EPS came in at -$0.95 falling short of the estimated -$0.75 by -26.67%.
Earnings released on 12 Nov 2020
EPS came in at -$1.35 falling short of the estimated -$0.75 by -80.00%.
MNPR Stock Performance
Access detailed MNPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.